Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload

Inclusion Criteria: * Transfusional iron overload due to: hereditary anemias such as sickle cell disease, β-thalassemia and Diamond-Blackfan anemia; acquired anemias such as Myelodysplastic Syndrome and other forms of bone marrow failure. Patients must also be transfusion-dependent and require chronic treatment with deferoxamine, deferasirox, and/or deferiprone. * Willing to discontinue all existing iron chelation therapies throughout study period. * Serum ferritin greater than 500 ng/mL at Screening. * Baseline liver iron concentration and cardiac MRI T2\* per protocol requirements. * Mean of the previous three pre-transfusion hemoglobin concentrations greater than or equal to 7.5 g/dL. * Agrees to use an approved method of contraception throughout study period. Exclusion Criteria: * As a result of medical review, physical examination or Screening investigations, the Principal Investigator considers the patient unfit for the study. * Non-elective hospitalization within the 30 days prior to Baseline testing. (Patients with sickle cell anemia who are admitted to the hospital for management of sickle crisis pain whose uncomplicated hospital course was four days or less and who, 14 days prior to Baseline testing, have returned to their previous health status are acceptable.) * Evidence of clinically relevant oral, cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immunologic, bone marrow or skin disorder as determined by the Inve…